CRMD
HealthcareCorMedix Inc. · Biotechnology · $620M
What is CorMedix Inc.?
CorMedix Inc. is a biopharmaceutical company focused on preventing and treating infectious and inflammatory diseases, with operations in the United States and internationally.
CorMedix develops anti-infective solutions designed to reduce catheter-related infections and thrombosis in patients who depend on central venous catheters. Its commercial focus spans hemodialysis, total parenteral nutrition, and oncology settings, where catheter-related complications represent a significant clinical burden.
Incorporated in 2006 and rebranded as CorMedix in January 2007, the company is headquartered in Berkeley Heights, New Jersey.
- DefenCath/Neutrolin anti-infective catheter lock solution
- Catheter-related infection prevention for hemodialysis patients
- Anti-thrombotic catheter protection in oncology and nutrition settings
Is CRMD a Good Stock to Buy?
UQS Score rates CRMD as Very Good overall.
CorMedix stands out for Strong Quality and Strong Risk scores — a combination that reflects financial discipline and a relatively contained risk profile for a small-cap biopharma. Valuation is rated Attractive, suggesting the market may not yet fully reflect the company's fundamentals.
Growth and Moat are both rated Neutral, indicating the company is still building commercial scale and competitive differentiation.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CRMD pay dividends?
No — CorMedix Inc. does not currently pay a dividend.
CorMedix does not currently pay a dividend. As a commercial-stage biopharmaceutical company, available capital is directed toward product commercialization, regulatory activities, and pipeline development rather than shareholder distributions.
When does CRMD report earnings?
CorMedix reports earnings on a quarterly cadence, consistent with US-listed equities.
The company's Strong Quality and Risk pillar ratings suggest a degree of financial stability relative to peers at a similar stage. Investors should monitor revenue progress tied to DefenCath's commercial rollout as a key indicator of near-term performance.
For the most recent quarter's results, visit CorMedix's investor relations page directly.
CRMD Price History
+65.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in CorMedix Inc.?
Based on CorMedix Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does CorMedix do?
CorMedix is a biopharmaceutical company that develops products to prevent catheter-related infections and thrombosis. Its lead product, DefenCath/Neutrolin, targets patients using central venous catheters in hemodialysis, oncology, and nutritional support settings.
Does CRMD pay dividends?
No, CRMD does not pay a dividend. The company reinvests its resources into commercializing DefenCath and advancing its pipeline, which is typical for small-cap biopharma companies at this stage of growth.
When does CRMD report earnings?
CorMedix follows a standard quarterly reporting cadence. For exact dates and the most recent results, check the investor relations section of the CorMedix website.
Is CRMD a good stock to buy?
UQS Score rates CRMD as Very Good, with Strong marks for Quality and Risk and an Attractive Valuation rating. Growth and Moat are Neutral, reflecting the early commercial stage. The full pillar breakdown is available to Pro members.
Is CRMD overvalued?
The UQS Valuation pillar rates CRMD as Attractive, suggesting the stock may be reasonably priced relative to its fundamentals. For the detailed valuation metrics behind this rating, a Pro account provides the complete view.
What is CRMD's market cap bracket?
CRMD is classified as a small-cap stock. This places it in a segment of the market that can offer growth potential but also carries higher volatility and liquidity risk compared to larger peers.
Is CRMD a long-term quality indicator?
The UQS framework evaluates long-term quality through five pillars. CRMD's Strong Quality and Risk scores are encouraging signals, though the Neutral Growth and Moat ratings suggest investors should track commercial execution over time.
What sector does CRMD belong to?
CRMD operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses on anti-infective and anti-inflammatory therapies for patients in clinical settings who rely on central venous catheters.
Unlock Full CRMD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind the Strong Quality and Risk ratings
- ✓Compare CRMD against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available exclusively to Pro members
Pro Analysis
CRMD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | 17.0 | 0.0 | 46.0 | 0.0 | 36.9 | 0.0 | -51.3 |
| Aug 8, 2026 | 68.3 | 97.1 | 46.0 | 52.6 | 99.8 | 47.0 | -1.7 |
| Jul 29, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.3 | 64.8 | 0.0 |
| Jul 23, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.3 | 64.4 | 0.0 |
| Jul 22, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.3 | 64.3 | 0.0 |
| Jul 21, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.3 | 64.5 | 0.0 |
| Jul 12, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.3 | 64.2 | 0.0 |
| Jul 11, 2026 | 70.0 | 97.1 | 46.0 | 52.6 | 99.4 | 64.2 | — |
CRMD — Pillar Breakdown
Quality
— 0.0/100 (25%)CorMedix Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)CorMedix Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 36.9/100 (15%)CorMedix Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)CorMedix Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 46/100 (25%)CorMedix Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CRMD.
Score Composition
Financial Data
More Stock Analysis
How is the CRMD UQS Score Calculated?
The UQS (Unified Quality Score) for CorMedix Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses CorMedix Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether CorMedix Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.